alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Order filed August 16, 2018. 

In The

Fourteenth Court of Appeals

____________

NO. 14-18-00710-CV

____________

SUZANNE SONDRUP RON, ON BEHALF OF HERSELF AND AS

TRUSTEE ON BEHALF OF THE SUZANNE RON 2012 FAMILY 

TRUST, Appellant

V.

AVISHAI RON, ET AL, Appellee

On Appeal from the 125th District Court

Harris County, Texas

Trial Court Cause No. 2017-19071

ORDER

On August 14, 2018, appellant filed a motion as asking this court to stay an 

anti-suit injunction and a temporary restraining order both dated August 3, 2018 and

entered in trial court number 2017-19071 by the Honorable Kyle Carter, Judge of 

the 125th District Court, in Harris County, Texas. See Tex. R. App. P. 29.3.

We grant the motion as to the anti-suit injunction but deny the motion as to 
the temporary restraining order. We ORDER the anti-suit injunction STAYED until 

a final decision by this court on the appeal or until further order of this court.

PER CURIAM

Panel consists of Justices Christopher, Busby, and Brown.
47 P.3d 761

INTERMEDIATE COURT OF APPEALS OF HAWAI'I

#### Coello v. Donnan

23838

04/09/2002

Affirmed
IV 

114TH CONGRESS 

1ST SESSION H. RES. 470 

Congratulating the National Institute of Nursing Research on the occasion 

of its 30th Anniversary. 

IN THE HOUSE OF REPRESENTATIVES 

OCTOBER 8, 2015 

Mrs. CAPPS (for herself and Mr. JOYCE) submitted the following resolution; 

which was referred to the Committee on Energy and Commerce 

RESOLUTION 

Congratulating the National Institute of Nursing Research 

on the occasion of its 30th Anniversary. 

Whereas the Institute of Medicine in 1983 recommended that 

nursing research be included in the mainstream of biomedical and behavioral science; 

Whereas the Congress established the National Center for 

Nursing Research within the National Institutes of 

Health to disseminate information related to basic and 

clinical nursing research through the passage of the 

Health Research Extension Act of 1985; 

Whereas the National Center for Nursing Research excelled 

in its purpose to support and provide research training, 

fellowships, and opportunities for our Nation’s nursing 

scientists; 


SSpencer on DSK4SPTVN1PROD with BILLS
2 

•HRES 470 IH 

Whereas the Congress, recognizing the contributions of the 

National Center for Nursing Research to improving quality care and health, redesignated the center the National 

Institute of Nursing Research (in this resolution referred 

to as the ‘‘NINR’’) through the passage of the National 

Institutes of Health Revitalization Act of 1993; 

Whereas the NINR’s research focus for the past 30 years encompasses advances in health and wellness promotion, 

managing symptoms of acute and chronic illnesses, as 

well as innovations in science and practice; 

Whereas the NINR’s mission is to promote and improve the 

health of individuals, families, communities, and populations, across all stages of life; 

Whereas the NINR’s goal is to enhance nursing science and 

health care by integrating the biological and behavioral 

sciences, applying new technologies, promoting health equity, and developing scientists of the future; 

Whereas NINR funded scientists conduct patient-centered, 

point-of-care, biobehavioral research with a primary focus 

on health promotion, symptom management, quality of 

care, and quality of life; 

Whereas the NINR has a commitment to helping eliminate 

health disparities facing minority, underserved, and disadvantaged populations across the Nation; 

Whereas the NINR is the lead institute for palliative and 

end-of-life care research at the National Institutes of 

Health; and 

Whereas the NINR invests a large portion of its budget to 

train emerging scientists, ensuring a strong body of nursing knowledge is generated for the health of the Nation: 

Now, therefore, be it 


SSpencer on DSK4SPTVN1PROD with BILLS
3 

•HRES 470 IH 

1 Resolved, That the House of Representatives— 

2 (1) congratulates the National Institute of 

3 Nursing Research on the occasion of its 30th Anni4 versary; and 

5 (2) commends the Institute for its ongoing sup6 port of nursing research integral to the health and 

7 well-being of Americans. 

Æ 


SSpencer on DSK4SPTVN1PROD with BILLS
#### Teller v. Teller

18728

7/24/98

Reversed, Vacated & Remanded
#### Doe, In re

22884

04/30/2002

Vacated and Remanded
Navigate to Homepage
Search
Main navigation
  

        
              Explore the Capitol Campus
                          Art
                            Buildings & Grounds
                            Capitol Hill Facts
                            Visitor Resources
                            Our Blog
                            What We Do
                          Areas of Expertise
                            Programs & Ceremonies
                            Projects
                            Publications
                            Strategic Objectives
                            About Us
                          Who We Are
                            History of the AOC
                            News & Notices
                            Organizational Structure
                            Partnerships & Recognition
                            Work With UsSearch Breadcrumb
    Homecommentreply584Add new comment
Add new comment
        
                  MICHAEL J LILLY (not verified)PermalinkDecember 20, 2022 - 4:28pmWONDERFUL DISPLAY, ESPECIALLY THE MANY TYPES OF ACTUAL PLANT DESIGN AND COLORS.  Thank You.
ReplyYour name
Email Address
        The content of this field is kept private and will not be shown publicly.
Comment
About text formats
Plain text
  
  
      
          No HTML tags allowed.
                      Lines and paragraphs break automatically.
                      Web page addresses and email addresses turn into links automatically. Serve. Preserve. Inspire.

              Contact Us
                            Accountability
                            Hill Staff Resources
                            AOC Staff Resources
Utility
  

        
              Privacy Policy
                            Image Terms of Use
                            Inspector General
                            U.S. Botanic Garden
                            U.S. Capitol Visitor CenterFacebook
	Twitter
	Flickr
	YouTube
	Instagram
	Subscribe
# C_2019131EN.01001801.xml

| 8.4.2019 | EN | Official Journal of the European Union | C 131/18 |
| --- | --- | --- | --- |

8.4.2019

EN

Official Journal of the European Union

C 131/18

---

Request for a preliminary ruling from the Consiglio di Stato (Italy) lodged on 9 November 2018 — Ascopiave SpA and Others v Ministero dello Sviluppo Economico and Others

(Case C-711/18)

(2019/C 131/23)

Language of the case: Italian

Referring court

Consiglio di Stato

Parties to the main proceedings

Appellants: Ascopiave SpA, Bim Belluno Infrastrutture SpA, Centria Srl, Retipiù Srl, Pasubio Distribuizione Gas Srl — Unipersonale, Pasubio Group SpA, Unigas Distribuzione Srl

Respondents: Ministero dello Sviluppo Economico, Presidenza del Consiglio dei Ministri, Ministero per gli Affari Regionali e le Autonomie

Questions referred

Does EU law and, in particular, the common rules governing the internal market in electrical energy and natural gas and the principles of legal certainty and protection of legitimate expectations allow retroactive application of the criteria for determining the amount of the reimbursements payable to former concession holders, thereby affecting previous contractual relationships, or can such application be justified, also in the light of the principle of proportionality, by the need to protect other public interests of European importance, relating to the necessity of improving protection for competition within the market in question and of affording greater protection to service users, who might indirectly bear the burden of an increase in the sums payable to former concession holders?

---
防止野生鳥類,老鼠和昆蟲的檢查表

家禽生活區域的食物、水和住所會吸引野生鳥類、老鼠和昆蟲。保護您的家禽免受這些有害之物携帶

的細菌和疾病至關重要:如蟎蟲和其它寄生蟲、禽流感等病毒、沙門氏菌和彎曲杆菌等細菌、或其它病

原體。無論您是大型商業企業的一員還是將養禽作爲業餘愛好,請確保接觸您的禽群的所有人都遵守

生物安全措施,以避免這些威脅。

如果您發現或懷疑有任何異常,請立即致電您的禽群主管、獸醫或合作推廣辦事處(cooperative 

extension office)。請使用此表單記錄您所在地區的聯絡人電話號碼。 您行動越早,就越容易將疾病

控制在一個禽群中。

檢查背面的清單,瞭解有助於保持您禽群健

康的提示。 √

動物與植物健康檢驗服務 (Animal and Plant Health Inspection Service)

如果您看到疾病跡象,請立即採取行動! 電話號碼

獸醫

合作推廣辦事處

州獸醫/動物或家禽診斷實驗室

USDA 866.536.7593

報告病禽

BIRDS Checklist Master-WildBirds_ZH-TW.indd 1 08-Jun-19 10:
請務必:

查明您所在區域野生鳥類的遷徙季節的具體時間。在此期間

需格外小心,以保護您的禽群免受傳染病的侵害。如果您發現

本地野生鳥巢內有鳥蛋或幼鳥,請聯繫您的合作推廣服務。

檢查表: 幫助保持您禽群健康的提示 

該檢查表是實施良好生物安全的一般指引,但如果您有特定場址的生物安全計劃,則請遵循該計劃。商

業養殖者應確保其特定場址計劃遵循《國家禽類改良計劃》(National Poultry Improvement Plan)的生

物安全原則。

瞭解導致疾病風險的因素:不僅僅是野生鳥類和有害之

物本身,羽毛、鳥巢、糞便和其它有機物也可携帶疾病。

這些東西可以通過家禽圍場、飼料和水源、甚至是您場

地中的車輛而與您的禽群發生接觸。 

定期檢查鶏舍、圍欄和禽舍中可使鳥類栖息、築巢或進

入的區域。這些包括屋檐延長處、屋頂通風、架空電綫、

撕裂的窗紗、孔洞和殘破的門洞。建築物墻壁周圍的混

凝土護墻可阻止穴居動物。

在築巢季節之前掃除舊巢——鳥類會年復一年地回到同

一個鳥巢。 

對家禽圍場進行清潔和消毒。這包括清除污垢垃圾並將

其扔掉。病鳥很容易污染草杆和其它草墊。

不要給野生鳥類、老鼠和昆蟲提供免費午餐!立即清除溢

出或未被吃掉的飼料,確保飼料儲存裝置安全且無孔。

保護您禽群的供水。確保野生鳥類、老鼠和其它害蟲無

法接觸它。如果可以的話,可以使用市政供水或經處理

的水,這樣您就知道它是乾淨的。

不要在有水禽或其它野生動物糞便的區域內穿行或駕

駛卡車、拖拉機或設備。如果您無法避免這種情况,請徹

底清潔鞋子、車輛和/或設備,以防止將病原體帶給您的

禽群。

瞭解家禽疾病的警告性信號,例如您的禽群吃喝多少的

變化、禽群死亡數量增加或全身不適等症狀。

√

USDA是平等機會提供者、雇主和出借者。

動物和植物健康檢驗服務(Animal and Plant Health Inspection Service)

項目援助編號2235-4 • 2018年11月簽發

如需瞭解更多關於如何保持禽群健康的信息,請關注 Facebook 和 Twitter 上的“保護禽群”

(Defend the Flock),並訪問 www.aphis.usda.gov/animalhealth/defendtheflock。

BIRDS Checklist Master-WildBirds_ZH-TW.indd 2 08-Jun-19 10:
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>

<ARTICLE>            5
<LEGEND>
This schedule contains summary financial information extracted from InfoNow's
Quarterly report to stockholders for the quarter ended March 31, 1998, and is
qualified in its entirety by reference to such financial statements.
</LEGEND> 
       
<S>                      <C>
<MULTIPLIER>                1,000
<PERIOD-TYPE>              QUARTER
<FISCAL-YEAR-END>      DEC-31-1998
<PERIOD-START>          JAN-1-1998
<PERIOD-END>           MAR-31-1998
<CASH>                         972
<SECURITIES>                     0
<RECEIVABLES>                  254
<ALLOWANCES>                     0
<INVENTORY>                      0
<CURRENT-ASSETS>              1264
<PP&E>                        1211
<DEPRECIATION>                 645
<TOTAL-ASSETS>                1919
<CURRENT-LIABILITIES>          947
<BONDS>                          0
<PREFERRED-MANDATORY>            0
<PREFERRED>                      0
<COMMON>                         6
<OTHER-SE>                     931
<TOTAL-LIABILITY-AND-EQUITY>  1919
<SALES>                        442
<TOTAL-REVENUES>               442
<CGS>                          405
<TOTAL-COSTS>                  744
<OTHER-EXPENSES>                 9
<LOSS-PROVISION>                0
<INTEREST-EXPENSE>             (4)
<INCOME-PRETAX>              (297)
<INCOME-TAX>                     0
<INCOME-CONTINUING>          (297)
<DISCONTINUED>                   0
<EXTRAORDINARY>                  0
<CHANGES>                        0
<NET-INCOME>                 (297)
<EPS-PRIMARY>                (.06)
<EPS-DILUTED>                (.06)


</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          OCT-31-2000
<PERIOD-END>                               APR-30-2000
<CASH>                                           41757
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                     418942
<CURRENT-ASSETS>                                     0
<PP&E>                                            5927
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                  517959
<CURRENT-LIABILITIES>                                0
<BONDS>                                         248288
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           110
<OTHER-SE>                                      199606
<TOTAL-LIABILITY-AND-EQUITY>                    517959
<SALES>                                         367176
<TOTAL-REVENUES>                                379286
<CGS>                                           308472
<TOTAL-COSTS>                                   308472
<OTHER-EXPENSES>                                 47582
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                  23232
<INCOME-TAX>                                      8503
<INCOME-CONTINUING>                              14729
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     14729
<EPS-BASIC>                                       1.33
<EPS-DILUTED>                                     1.33


</TABLE>
#### State v. Whitfield

22516

01/12/2001

Affirmed
EXHIBIT
23




[LETTERHEAD OF BKD LLP]





Consent
of Independent Registered Public Accounting Firm





We hereby
consent to the incorporation by reference in the Registration Statements on Form
S-8 (File Numbers 333-04013, 333-56111 and 333-139711) of our report dated
March 30, 2010, on our audits of the consolidated financial statements of
Ameriana Bancorp as of December 31, 2009 and 2008 and for the years then ended,
which report is included in Ameriana Bancorp’s Annual Report on Form 10-K for
the fiscal year ended December 31, 2009.






/s/BKD,LLP
 BKD LLP
 Indianapolis,
Indiana
 March 31,
2010
1... This proceeding arises out of Cause No. 2007-CR-2049, styled The State of Texas v. Darryl B. Wells, in the

379th Judicial District Court, Bexar County, Texas, the Honorable Bert Richardson presiding.

i i i i i i

MEMORANDUM OPINION

No. 04-08-00899-CR

IN RE Daryl WELLS

Original Mandamus Proceeding1

PER CURIAM

Sitting: Karen Angelini, Justice

Phylis J. Speedlin, Justice

Steven C. Hilbig, Justice

Delivered and Filed: December 23, 2008

PETITION FOR WRIT OF MANDAMUS DENIED

Daryl Wells filed a pro se petition for a writ of mandamus on December 11, 2008. Wells was

sentenced August 28, 2008, and filed a notice of appeal on August 29, 2008. The trial court

appointed the Bexar County Public Defender’s Office to represent Wells on appeal. In this pro se

petition, Wellsseeksto compel the trial court to “rule on court reporter’s record and trial transcripts

motions.” We conclude Wells’ appointed counsel is also counsel for an original proceeding on the

issue presented. Wells is not entitled to hybrid representation. See Patrick v. State, 906 S.W.2d 481,

498 (Tex. Crim. App. 1995); Gray v. Shipley, 877 S.W.2d 806, 806 (Tex. App.–Houston [1st Dist.]

1994, orig. proceeding). Accordingly, the pro se petition for a writ of mandamus is denied. See TEX.

R. APP. P. 52.8(a).
04-08-00899-CR

-2-

The clerk of this court is directed to transmit a copy of this opinion to the attorneys of record,

the trial court judge, and the trial court clerk.

PER CURIAM

Do not publish
August 11, 2000

22572

#### State v. Kosky

Affirmed
/**
 * @file
 * Attaches behavior for the Filter module.
 */

(function ($, Drupal) {
  /**
   * Displays the guidelines of the selected text format automatically.
   *
   * @type {Drupal~behavior}
   *
   * @prop {Drupal~behaviorAttach} attach
   *   Attaches behavior for updating filter guidelines.
   */
  Drupal.behaviors.filterGuidelines = {
    attach(context) {
      function updateFilterGuidelines(event) {
        const $this = $(event.target);
        const { value } = event.target;
        $this
          .closest('.js-filter-wrapper')
          .find('[data-drupal-format-id]')
          .hide()
          .filter(`[data-drupal-format-id="${value}"]`)
          .show();
      }

      $(once('filter-guidelines', '.js-filter-guidelines', context))
        .find(':header')
        .hide()
        .closest('.js-filter-wrapper')
        .find('select.js-filter-list')
        .on('change.filterGuidelines', updateFilterGuidelines)
        // Need to trigger the namespaced event to avoid triggering formUpdated
        // when initializing the select.
        .trigger('change.filterGuidelines');
    },
  };
})(jQuery, Drupal);
Breadcrumb

1. Home

2. Print 

3. Pdf 

4. Node 

5. Entity Print 

PCN Quarantine Information

November 29, 2021

Last Modified: 

Print

The following changes have been made to the pale cyst nematode (PCN) regulated

area since the November 22, 2021 publication:

In accordance with the Federal PCN Final Rule, subpart 301.86-3(c)(1) Criteria for

designation of fields as infested fields and associated fields - Infested fields, one field

in Bingham County, Idaho was confirmed PCN-positive on November 29, 2021.  The

97-acre field, under regulation since 2011 due to its association with another PCNinfested field, was detected by a routine delimiting survey. This detection will not

add any new associated fields to the regulated area.

With these changes, the current regulated area is 6,570 acres, of which 3,542 acres

are infested fields and 3,028 acres are associated fields.

Regulated Quarantine Map (586.23 KB)

Loading...
Breadcrumb

1. Hogar

2. Print 

3. Pdf 

4. Node 

5. Entity Print 

Take a Pet From One U.S. State or

Territory to Another (Interstate)

Last Modified: 

Print

When you travel with a pet, your destination State or Territory may have animal

health requirements, such as obtaining a health certificate, updating vaccinations,

diagnostic testing, or administering treatments. As soon as you know your travel

details, contact your local veterinarian to help with the pet travel process.

Find U.S. State and Territory Requirements

State Animal Health Officials
APHIS doesn't regulate the interstate movement of pets. Domestic movement

requirements are set by the receiving State or Territory.

Contact the State animal health official in your destination State or Territory if you

have questions or need clarification on any of the requirements.
**Exhibit 32.1**

**SECTION 1350 CERTIFICATION**

In connection with the AnnualReport of Home Solutions of America, Inc. (the "Company") on Form10-KSB for the annual period ended December 31, 2005 as filed with theSecurities and Exchange Commission on the date hereof (the "Report"),I, Frank Fradella, Chief Executive Officer of the Company, certify, pursuant to18 U.S.C. Section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002, that: 

(1)     The Reportfully complies with the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and 

(2)     Theinformation contained in the Report fairly presents, in all material respects,the financial condition and result of operations of the Company. 

 

| Date: March 31, 2006 | /s/Frank FradellaFrank Fradella, Chief Executive Officer |
|----------------------|----------------------------------------------------------|
[Federal Register Volume 88, Number 235 (Friday, December 8, 2023)]
[Notices]
[Pages 85628-85629]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-26994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2023-N-3859]


Dr. Reddy's Laboratories, Inc.; Withdrawal of Approval of 11 
Abbreviated New Drug Applications; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice 
that appeared in the Federal Register on October 4, 2023. The document 
announced the withdrawal of approval of 11 abbreviated new drug 
applications (ANDAs) from Dr. Reddy's Laboratories, Inc., withdrawn as 
of November 3, 2023. The document indicated that FDA was withdrawing 
approval of ANDA 203807, clozapine tablets, 25 milligrams (mg), 50 mg, 
100 mg, and 200 mg, held by Dr. Reddy's Laboratories, Inc., U.S. Agent 
for Dr. Reddy's Laboratories SA, 107 College Rd. East, Princeton, NJ 
08540. Before FDA withdrew the approval of this ANDA, Dr. Reddy's 
Laboratories, Inc., informed FDA that it did not want the approval of 
the ANDA withdrawn. Because Dr. Reddy's Laboratories, Inc., timely 
requested that approval of ANDA 203807 not be withdrawn, the approval 
is still in effect. This notice corrects that error.

FOR FURTHER INFORMATION CONTACT: Martha Nguyen, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 240-
402-6980, <a href="/cdn-cgi/l/email-protection#f4b99586809c95daba93818d919ab4929095da9c9c87da939b82"><span class="__cf_email__" data-cfemail="afe2cedddbc7ce81e1c8dad6cac1efc9cbce81c7c7dc81c8c0d9">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: In the Federal Register of Wednesday, 
October 4, 2023 (88 FR 68628), appearing on

[[Page 85629]]

page 68629 in FR Doc. 2023-21992, the following correction is made:
    On page 68629, in the table, the entry for ANDA 203807 is removed.

    Dated: December 5, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-26994 Filed 12-7-23; 8:45 am]
BILLING CODE 4164-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
28454

#### State v. Anh Cong Bui

Affirmed